



Response document for MHRA public consultation on the
proposal to make Dovonex Psoriasis Ointment available in Pharmacies
Ref: ARM95

ANNEX 1

Your details

Name: [REDACTED]

Position (if applicable): Chief Executive

Organisation (if applicable): Dispensing Doctors' Association

Email: [REDACTED]

1. Do you consider that Dovonex Psoriasis Ointment should be available as a Pharmacy medicine?

Yes

Please provide any comments or evidence to support your response:

N/A

2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Dovonex Psoriasis Ointment?

N/A

3. Do you have any other comments on the reclassification?

N/A

4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

No

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gsi.gov.uk) to arrive by **20 April 2017**. Contributions received after that date cannot be included in the exercise.